JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Effect of Small Extracellular Vesicles Produced by Mesenchymal Stem Cells on 5xFAD Mice Hippocampal Cultures

  • 0Institute of Cell Biophysics, Federal Research Center Pushchino Research Center for Biological Studies, Russian Academy of Sciences, Institutskaya 3, Pushchino, 142290 Moscow, Russia.
International Journal of Molecular Sciences +

|

May 14, 2025

|

May 14, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Small extracellular vesicles (sEVs) show promise for Alzheimer's disease (AD) treatment. These vesicles reduced amyloid-beta peptide and improved synaptic density in an in vitro AD model, suggesting therapeutic potential for neurodegenerative diseases.

Area Of Science

  • Neuroscience
  • Cell Biology
  • Biotechnology

Background

  • Alzheimer's disease (AD) is a progressive neurodegenerative disorder impacting memory and cognition.
  • Current therapeutic strategies for AD are limited, necessitating the development of novel treatments.
  • Small extracellular vesicles (sEVs) are emerging as potential therapeutic agents for neurodegenerative conditions.

Purpose Of The Study

  • To investigate the therapeutic potential of sEVs derived from human mesenchymal stem cells (MSCs) in an in vitro model of Alzheimer's disease.
  • To characterize the effects of MSC-derived sEVs on neuronal and synaptic health in an AD context.

Main Methods

  • sEVs were isolated from human Wharton's jelly MSCs using asymmetric depth filtration.
  • An in vitro AD model was established using hippocampal cells from 5xFAD transgenic mice.
  • sEVs were characterized using electron microscopy, nanoparticle tracking analysis, and molecular assays.
  • The impact of sEVs on Aβ peptide levels and synaptic density was assessed.

Main Results

  • Isolated sEVs were characterized and confirmed for their properties.
  • MSCs-derived sEVs demonstrated no toxicity to 5xFAD hippocampal cells.
  • sEVs successfully colocalized with neurons and astrocytes within the AD model.
  • Treatment with sEVs led to a significant decrease in Aβ peptide levels.
  • sEVs treatment resulted in a notable increase in synaptic density.

Conclusions

  • MSCs-derived sEVs exhibit neuroprotective effects in an in vitro AD model.
  • sEVs may improve brain cell function and reduce AD risk.
  • These findings support the potential of sEVs as a novel therapeutic approach for Alzheimer's disease.

Keywords: